Sinovac's COVID-19 Vaccine Found Very Effective in Turkey

The Lancet published a COVID-19 vaccine study by Mine Durusu Tanriover and colleagues on July 8, 2021, presenting interim results of a double-blind, randomized, controlled trial of CoronaVac versus placebo in Turkey.

The results of the phase 3 trial in Turkey indicated that, in a population aged 18–59 years, the CoronaVac vaccine had high efficacy for preventing symptomatic COVID-19 (83·5% relative to placebo) and COVID-19-related hospitalization (100%) at least 14 days after the second dose.

A related commentary also published by The Lancet stated, 'Tanriover and colleagues' study suggests that CoronaVac is another useful tool in the global fight against COVID-19, although more data are needed on its efficacy against emerging SARS-CoV-2 variants and on its duration of protection across different age groups and geographical settings and in the presence of comorbidities.'

Sinovac Biotech's CoronaVac COVID-19 vaccine is based on an inactivated pathogen made by growing the whole virus in a lab and then killing it. CoronaVac is a 2-dose β-propiolactone-inactivated, aluminum hydroxide-adjuvanted COVID-19 vaccine administered on a 0/14-28-day schedule to prevent COVID-19.